Company Announcements - 2021
-
Notification of Cessation of Securities and Appendix 3Y's22 December 2021
Analytica provides notification regarding the cessation of various options and associated Appendix 3Y announcements for Directors.
-
Results of Annual General Meeting25 November 2021
Analytica presents the voting results for resolutions at the Annual General Meeting. The company also presents the Chairman's address to shareholders and slides from the CEO presentation.
-
US Patent Grant for PeriCoach11 November 2021
Analytica announces the granting of patent protection in the USA for the arrangement of force sensors in pelvic floor exercise devices.
-
Jobkeeper Payments Notification9 November 2021
A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001- jobkeeper payments disclosure by listed entity.
-
Appendix 4C29 Oct 2021
Analytica presents its quarterly cash flow report to 30 September 2021.
-
Notice of Annual General Meeting20 October 2021
Analytica presents a Letter to shareholders, Notice of Annual General Meeting, and a sample Proxy form.
-
Annual Report, Appendix 4G, and Corporate Governance Statement30 September 2021
Analytica presents its Annual Report, Corporate Governance Statement, and Appendix 4G.
-
Closing Date for Director Nominations16 September 2021
For the purpose of ASX Listing Rule 3.13.1, the closing date for director nominations will be 24 Sept 2021
-
Manufacturing Strategy Update and Queensland Government Support06 September 2021
Analytica wishes to update shareholders on its strategy to manufacture and supply its PeriCoach product to meet prospective demand, and financial support offered by the Queensland Government under its Advance Queensland Industry Attraction Fund (AQIAF).
-
Appendix 4E Preliminary Final Report31 August 2021
Analytica presents its Preliminary Final Report.
-
Appendix 4C30 Jul 2021
Analytica presents its quarterly cash flow report to 30 June 2021.
-
Change of Substantial and Directors' Holdings22 June 2021
-
Appendix 2A - Options Issued21 June 2021
-
Results of EGM18 June 2021
-
Cleansing Prospectus17 June 2021
-
Notice of Extraordinary General Meeting17 May 2021
Notice is given that an Extraordinary General Meeting will be held at 10am on Friday, 18 June 2021 in the Mayflower Room, 320 Adelaide Street, Brisbane, Australia
-
Form 60430 April 2021
Notice of change of interests of substantial holders Dr Michael Monsour and Dr Peter Corr.
-
US Patent Grant for PeriCoach30 April 2021
Analytica announces the granting of patent protection in the USA for motion sensing in pelvic floor exercise devices.
-
Appendix 4C29 April 2021
Analytica presents its quarterly cash flow report to 31 March 2021.
-
Notice under section 708A and Appendix 2A28 April 2021
Analytica has today issued 879,903,083 fully paid ordinary shares in the Company at an issue price of 0.35 cents per share.
-
Placement to Raise up to $3.83m23 April 2021
Analytica announce a share placement at an issue price of 0.35 cents per share which will raise up to $3.83 million subject to shareholder approval.
-
Trading Halt21 April 2021
ASX advises that Analytica securities have been placed in a trading halt pending an announcement regarding capital raising.
-
Expansion of Enhanced Infusion System into Middle East20 April 2021
Analytica has entered into an agreement with an Egyptian entity to distribute and market the EIS in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and UAE.
-
Half Year Report to 31 Dec 202031 March 2021
Analytica presents its audited Half year results to 31 December 2020.
-
Expansion into China with PeriCoach JV30 March 2021
Analytica has entered into a joint venture agreement to manufacture, distribute and market the system in China, Macau, Hong Kong and Taiwan
-
Appendix 4D and Half Year accounts lodged under ASX Extended Class waiver26 February 2021
Analytica presents its Appendix 4D - Half year results to 31 December 2020.
-
Appendix 4C29 January 2021
Analytica presents its quarterly cash flow report to 31 December 2020.